AnaptysBio, Inc. (ANAB) PT Set at $69.00 by Robert W. Baird
AnaptysBio, Inc. (NASDAQ:ANAB) has been assigned a $69.00 target price by stock analysts at Robert W. Baird in a research report issued to clients and investors on Wednesday. The firm presently has a “buy” rating on the biotechnology company’s stock. Robert W. Baird’s target price points to a potential downside of 2.00% from the stock’s current price.
Several other research firms also recently issued reports on ANAB. JMP Securities upped their price objective on AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a research note on Tuesday. Zacks Investment Research downgraded AnaptysBio from a “buy” rating to a “hold” rating in a research note on Tuesday, August 29th. Credit Suisse Group upped their price objective on AnaptysBio from $38.00 to $85.00 in a research note on Tuesday. Finally, Royal Bank Of Canada began coverage on shares of AnaptysBio in a research report on Thursday, September 14th. They set an “outperform” rating and a $40.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus target price of $59.14.
AnaptysBio (NASDAQ ANAB) traded down 1.08% during midday trading on Wednesday, reaching $69.65. 584,544 shares of the company’s stock traded hands. The stock has a 50-day moving average of $35.88 and a 200 day moving average of $35.88. AnaptysBio has a 52-week low of $15.17 and a 52-week high of $74.00. The company’s market cap is $1.42 billion.
AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.29. The firm had revenue of $7.00 million during the quarter, compared to analyst estimates of $3.45 million. On average, analysts anticipate that AnaptysBio will post ($1.98) earnings per share for the current fiscal year.
In other AnaptysBio news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total transaction of $901,924.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Holdings A/S Novo sold 356,300 shares of the stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $21.10, for a total transaction of $7,517,930.00. Following the sale, the insider now directly owns 1,936,604 shares of the company’s stock, valued at approximately $40,862,344.40. The disclosure for this sale can be found here. Insiders have sold a total of 1,133,940 shares of company stock valued at $24,223,316 in the last three months.
A number of large investors have recently added to or reduced their stakes in ANAB. Bank of New York Mellon Corp acquired a new stake in AnaptysBio during the 1st quarter valued at approximately $373,000. JPMorgan Chase & Co. acquired a new stake in AnaptysBio during the 1st quarter valued at approximately $3,851,000. TIAA CREF Investment Management LLC acquired a new stake in AnaptysBio during the 1st quarter valued at approximately $227,000. MARSHALL WACE ASIA Ltd acquired a new stake in AnaptysBio during the 1st quarter valued at approximately $6,924,000. Finally, Marshall Wace North America L.P. acquired a new stake in AnaptysBio during the 1st quarter valued at approximately $6,924,000. 71.35% of the stock is owned by institutional investors and hedge funds.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.